Tonix Pharmaceuticals reported a net loss of $32 million in Q3 2025 as the company ramped up commercial operations for the upcoming Tonmya launch. Revenues increased modestly, but elevated R&D and SG&A expenditures weighed heavily on the bottom line.

In Q2 2025, Tonix generated $2.0M in net product revenue, slightly down from $2.2M in Q2 2024. R&D expenses increased to $10.8M, and G&A expenses more than doubled to $16.2M, largely due to pre-launch activities for TNX-102 SL. The company reported a net loss of $28.3M, or $3.86 per share, and ended the quarter with $125.3M in cash and cash equivalents.

Tonix Pharmaceuticals reported a net loss of $16.8 million for Q1 2025, an increase from the $14.9 million net loss in Q1 2024. Product revenue was relatively stable at $2.4 million. The company ended the quarter with $131.7 million in cash and cash equivalents and anticipates funding operations into the second quarter of 2026.

Tonix Pharmaceuticals reported a net loss of $22.1 million for Q4 2024, with product revenue of $2.6 million. The company's cash and cash equivalents stood at $98.8 million as of December 31, 2024, and it expects to have sufficient cash to fund operations beyond the FDA PDUFA goal date for TNX-102 SL.

Tonix Pharmaceuticals reported a net loss of $29.0 million, or $0.69 per share, for the third quarter ended September 30, 2022. The company's cash and cash equivalents totaled approximately $140 million as of September 30, 2022. Tonix is advancing multiple programs within its pipeline, with several Phase 2 or 3 studies expected to be in the clinic by the first quarter of 2023.

Tonix Pharmaceuticals reported $140.4 million in cash and cash equivalents as of March 31, 2022. The company's R&D expenses were $18.4 million, and G&A expenses were $8.0 million for the first quarter of 2022. Net loss per common share was $0.05.